{"id":"metronidazole-cefuroxime","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-15","effect":"Metallic taste (metronidazole)"},{"rate":"2-5","effect":"Headache"},{"rate":"1-3","effect":"Allergic reaction (cephalosporin)"},{"rate":"<1","effect":"Pseudomembranous colitis"}]},"_chembl":{"chemblId":"CHEMBL2146124","moleculeType":"Small molecule","molecularWeight":"446.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metronidazole is a nitroimidazole that generates reactive oxygen species in anaerobic bacteria, damaging their DNA and causing cell death. Cefuroxime is a second-generation cephalosporin that inhibits bacterial peptidoglycan cross-linking, weakening the cell wall. Together, they provide broad-spectrum coverage against both anaerobic and aerobic bacteria, commonly used in mixed infections.","oneSentence":"This combination uses metronidazole to disrupt bacterial DNA and cefuroxime to inhibit bacterial cell wall synthesis, together targeting anaerobic and aerobic pathogens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:04.276Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mixed aerobic-anaerobic bacterial infections"},{"name":"Intra-abdominal infections"},{"name":"Gynecological infections"},{"name":"Surgical site infections"}]},"trialDetails":[{"nctId":"NCT05784311","phase":"PHASE4","title":"Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-03-06","conditions":"Pancreatic Cancer","enrollment":344},{"nctId":"NCT04803422","phase":"NA","title":"Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2021-04-01","conditions":"Complicated Appendicitis","enrollment":3193},{"nctId":"NCT04755179","phase":"","title":"Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population","status":"COMPLETED","sponsor":"Ramon Gorter","startDate":"2019-08-12","conditions":"Appendicitis, Appendix Mass, Appendicitis Perforated","enrollment":1308},{"nctId":"NCT04510558","phase":"NA","title":"Reducing the Incidence of Incisional Hernia After Stoma Closure Using a Prophylactic Mesh","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2021-05-01","conditions":"Incisional Hernia","enrollment":72},{"nctId":"NCT04378868","phase":"PHASE4","title":"Role of Delay and Antibiotics on Perforation Rate While Waiting Appendectomy","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2020-05-18","conditions":"Appendicitis","enrollment":1800},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Appendicitis","enrollment":1552},{"nctId":"NCT04723472","phase":"NA","title":"Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment","status":"SUSPENDED","sponsor":"Shanghai East Hospital","startDate":"2023-08-01","conditions":"Helicobacter Pylori Infection","enrollment":82},{"nctId":"NCT04161599","phase":"PHASE4","title":"Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial.","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2022-03-01","conditions":"Wounds and Injuries, Surgery--Complications","enrollment":968},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":"Acute Infection","enrollment":589},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02916134","phase":"NA","title":"Conservative Versus Operative ManageMent of Acute Uncomplicated Appendicitis","status":"COMPLETED","sponsor":"Beaumont Hospital","startDate":"2016-09-12","conditions":"Appendicitis","enrollment":186},{"nctId":"NCT02505581","phase":"PHASE4","title":"Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-05","conditions":"Surgical Wound Infection","enrollment":536},{"nctId":"NCT04009772","phase":"PHASE2, PHASE3","title":"Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-07-01","conditions":"Emergency Cesarean Section, Infection Wound","enrollment":500},{"nctId":"NCT01790529","phase":"PHASE4","title":"Randomized Controlled Trial to Evaluate the Optimal Timing of Surgical Antimicrobial Prophylaxis","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2013-02","conditions":"Surgical Site Infection","enrollment":5000},{"nctId":"NCT01283815","phase":"PHASE2","title":"Laparoscopic Management of Periappendicular Abscess","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2011-01","conditions":"Appendicitis, Abdominal Abscess","enrollment":60},{"nctId":"NCT00613769","phase":"PHASE4","title":"Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery","status":"COMPLETED","sponsor":"Halmstad County Hospital","startDate":"2007-09","conditions":"Infection Prophylaxis in Colo Rectal Surgery","enrollment":1073},{"nctId":"NCT01524081","phase":"PHASE3","title":"Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures","status":"COMPLETED","sponsor":"The Faculty Hospital Na Bulovce","startDate":"2008-07","conditions":"Acute Appendicitis, Perforated Gastroduodenal Ulcer, Small Bowel Obstruction","enrollment":187},{"nctId":"NCT00557453","phase":"","title":"The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2008-04","conditions":"Acute Cholecystitits","enrollment":120},{"nctId":"NCT00355602","phase":"NA","title":"Antibiotics for the Treatment of Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-07","conditions":"Colitis, Ulcerative","enrollment":40},{"nctId":"NCT00713999","phase":"NA","title":"Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2001-08","conditions":"Sexually Transmitted Infections, Schistosoma Haematobium","enrollment":680}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zinacef 750mg (Cefuroxime 750mg, Glaxo Group Ltd., UK)","Metronidazol 500mg (Metronidazole 500mg; B.Braun Melsungen AG, Germany)"],"phase":"phase_3","status":"active","brandName":"Metronidazole, Cefuroxime","genericName":"Metronidazole, Cefuroxime","companyName":"The Faculty Hospital Na Bulovce","companyId":"the-faculty-hospital-na-bulovce","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses metronidazole to disrupt bacterial DNA and cefuroxime to inhibit bacterial cell wall synthesis, together targeting anaerobic and aerobic pathogens. Used for Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections, Gynecological infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}